Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.

Conference Presentation Details:

Event: Cowen & Co. 40th Annual Health Care Conference
Date/Time: Monday, March 2, 2020 at 2:50 p.m. ET
Location: Boston, MA

Event: Barclays Global Healthcare Conference
Date/Time: Tuesday, March 10, 2020 at 4:20 p.m. ET
Location: Miami, FL

Live webcasts for the Cowen & Co. and Barclays conference analyst-moderated fireside chats may be accessed on the Investors & Media page of the Company's website at www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, pulmonary, and neuromuscular diseases. In hematology, Acceleron and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial. The company is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Contacts

Acceleron Pharma Inc.
Investors:
Todd James, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations

or

Media:
Matt Fearer, (617) 301-9557
Director, Corporate Communications

Contacts

Acceleron Pharma Inc.
Investors:
Todd James, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations

or

Media:
Matt Fearer, (617) 301-9557
Director, Corporate Communications